Table 2 Cost Estimates (US $)
Parameters | Baseline value | Range | Reference | Distribution | |
|---|---|---|---|---|---|
Minimum | Maximum | ||||
Drug cost, $/per cycle | |||||
Olaparib | 3,657 | 2,926 | 4,388 | (27) | Gamma |
Bevacizumab | 7,326 | 5,861 | 8,791 | (28) | Gamma |
Carboplatin | 23 | 18 | 28 | (28) | Gamma |
Paclitaxel | 35 | 28 | 42 | (28) | Gamma |
Cost of AEs | |||||
Bevacizumab | 76 | 61 | 91 | (24) | Gamma |
Olaparib plus bevacizumab | 291 | 233 | 349 | (24, 29) | Gamma |
Laboratory per cycle | 4 | 3 | 5 | (27) | Gamma |
Tumor imaging per cycle | 105 | 84 | 126 | (24) | Gamma |
Administration per cycle | 124 | 99 | 149 | (24) | Gamma |
Germline BRCA testing per patient | 2,901 | 2,321 | 3,481 | (30) | Gamma |
HRD test per patient | 4,682 | 3,746 | 5,618 | (30) | Gamma |
Best supportive care per cycle | 4,143 | 3,314 | 4,972 | (31) | Gamma |
Terminal care per patient | 85,904 | 68,723 | 103,085 | (24) | Gamma |